Union européenne - français - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - luspatercept - anemia; myelodysplastic syndromes; beta-thalassemia - d'autres antianémique préparations - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5. reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.

Canada - français - Health Canada

celgene inc - luspatercept - poudre pour solution - 25mg - luspatercept 25mg - hematopoietic agents

Canada - français - Health Canada

celgene inc - luspatercept - poudre pour solution - 75mg - luspatercept 75mg - antianemia drugs